Our pre-clinical data strongly suggests that therapeutic targeting of CTCL using BET inhibition, alone or in combination with BCL2 inhibition or HDAC inhibition, represents a promising strategy in the treatment of CTCL that warrants clinical testing. This evidence concerns the gene BCL2 and primary cutaneous T-cell non-Hodgkin lymphoma.